6,7-二甲氧基喹唑啉-4-酮 | 13794-72-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6,7-二甲氧基喹唑啉-4-酮
• 中文别名: 6,7-二甲氧基喹唑啉酮；6,7-二甲氧基-3H-喹唑啉-4-酮；吉非替尼中间体2；6,7-二甲氧基-4-(1H)-喹唑啉酮；6,7-二甲氧基-4-羟基喹唑啉；6,7-二甲氧基-4-喹唑酮；6,7-二甲氧基-1H-喹唑啉-4-酮；6,7-二甲氧基-4(3H)-喹唑啉酮；6,7-二甲氧基-4-(3H)喹唑啉酮；6,7-二甲氧基-4-喹唑啉酮
• 英文名称: 3H-6,7-dimethoxyquinazolin-4-one
• 英文别名: 6,7-dimethoxy-4(3H)-quinazolinone；6,7-dimethoxyquinazolin-4(3H)-one；6,7-dimethoxyquinazoline-4(3H)-one；6,7-dimethoxy-1H-quinazolin-4-one；6,7-dimethoxy-3H-quinazolin-4-one
• CAS: 13794-72-4
• 化学式: C₁₀H₁₀N₂O₃
• mdl: MFCD04618149
• 分子量: 206.201
• InChiKey: DMSRMHGCZUXCMJ-UHFFFAOYSA-N

物化性质

• 熔点：
  309-311°C
• 沸点：
  374.1±52.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  室温

SDS

6,7-Dimethoxy-3H-quinazolin-4-one Revision number: 6
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: 6,7-Dimethoxy-3H-quinazolin-4-one

Revision number: 6

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Skin corrosion/irritation Category 2
Category 2A
Serious eye damage/eye irritation
ENVIRONMENTAL HAZARDS Not classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal word Warning
Hazard statements Causes skin irritation
Causes serious eye irritation
Precautionary statements:
Wash hands thoroughly after handling.
[Prevention]
Wear protective gloves/eye protection/face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
[Response]
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: 6,7-Dimethoxy-3H-quinazolin-4-one
Percent: >98.0%(HPLC)(T)
CAS Number: 13794-72-4
Synonyms: 6,7-Dimethoxy-4(3H)-quinazolinone , 6,7-Dimethoxy-3,4-dihydroquinazolin-4-one ,
6,7-Dimethoxy-4-hydroxyquinazoline , 6,7-Dimethoxy-4-quinazolinol
Chemical Formula: C10H10N2O3
6,7-Dimethoxy-3H-quinazolin-4-one

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
from the chemical: generate poisonous fume.
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store under inert gas.
Store away from incompatible materials such as oxidizing agents.
Air-sensitive
Comply with laws.
Packaging material:

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Safety glasses. A face-shield, if the situation requires.
Eye protection:
Skin and body protection: Protective clothing. Protective boots, if the situation requires.
6,7-Dimethoxy-3H-quinazolin-4-one

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: Crystal- Powder
White - Very pale yellow
Colour:
Odour: No data available
pH: No data available
Melting point/freezing point:298°C
No data available
Boiling point/range:
Flash point: No data available
Flammability or explosive
limits:
No data available
Lower:
Upper: No data available
No data available
Relative density:
Solubility(ies):
No data available
[Water]
[Other solvents] No data available

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx)
products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
No data available
NTP =
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobility in soil
Log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.
6,7-Dimethoxy-3H-quinazolin-4-one

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not listed

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6,7-二甲氧基喹唑啉-4-酮简介

6,7-二甲氧基喹唑啉-4-酮是一种常见的有机合成中间体。其熔点为309至311摄氏度，密度为1.33。常温常压下，它表现为浅米色固体粉末。该化合物在二甲基亚砜中溶解性不高，在甲醇中有一定的溶解度，并不溶于水。

用途

作为常见的有机合成中间体，6,7-二甲氧基喹唑啉-4-酮主要用于生物活性分子或药物分子的合成过程中。其酮的存在形式可发生烯醇式的互变异构，因此后续转化可以围绕羟基进行，例如将其转化为氯单元，并使氮杂环结构变为芳香性结构。此外，该化合物中的两个甲氧基可以选择性地脱去一个或同时脱去两个形成酚或双酚化合物。

环境危害

6,7-二甲氧基喹唑啉-4-酮作为一种含氮杂环有机物，对水环境具有潜在的危害。因此，在处理该物质时，应避免未稀释或大量产品接触地下水、水道或污水系统。

反应信息

• 作为反应物：
  描述：

  6,7-二甲氧基喹唑啉-4-酮 在 吡啶 、 氯化亚砜 、 氢溴酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 9.0h， 生成 埃罗替尼
  参考文献：
  名称：

  具有抗肿瘤活性的厄洛替尼衍生物及其制备方法和应用

  摘要：

  本发明公开了一种具有抗肿瘤活性的厄洛替尼衍生物及其制备方法和应用，属于具有抗肿瘤活性药物的合成技术领域。本发明的技术方案要点为：具有抗肿瘤活性的厄洛替尼衍生物，其结构式为：，其中R为苯基、对甲基苯基、间硝基苯基、邻氯苯基或邻羟基苯基。本发明还公开了该具有抗肿瘤活性的厄洛替尼衍生物的具体合成过程及其在制备治疗肝癌药物中的应用。本发明通过对厄洛替尼分子进行了改造，在其结构上连接一系列不同的1,2,3‑三氮唑基团，并对合成的厄洛替尼衍生物进行了抗肿瘤活性测试，发现该类化合物对肝癌HepG2细胞具有较好的抑制活性。

  公开号：

  CN106632271A
• 作为产物：
  描述：

  藜芦酸 在 硫酸 、 palladium on activated charcoal 、 氢气 、 硝酸 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 生成 6,7-二甲氧基喹唑啉-4-酮
  参考文献：
  名称：

  用于肿瘤 PET 成像的具有低亲脂性的新型 F-18 标记喹唑啉衍生物的合成和评价

  摘要：

  四种具有低亲脂性的新型 18 F 标记喹唑啉衍生物，[18 F]4-(2-氟乙氧基)-6,7-二甲氧基喹唑啉 ([18 F]I)，[18 F]4-(3-((4- (2-氟乙氧基)-7-甲氧基喹唑啉-6-基)氧基)丙基)吗啉([18 F]II)、[18 F]4-(2-氟乙氧基)-7-甲氧基-6-(2-甲氧基乙氧基)喹唑啉 ([18 F]III) 和 [18 F]4-(2-氟乙氧基)-6,7-双(2-甲氧基乙氧基)喹唑啉 ([18 F]IV) 通过两步放射合成程序合成总放射化学产率为 10% 至 38%（无衰减校正），放射化学纯度>98%。在体外测试了标记化合物的亲脂性和稳定性。4 种放射性示踪剂的 log P 值范围从 0.52 到 1.07。然后我们进行了 ELISA 以测量它们对 EGFR-TK 的亲和力；ELISA 测定结果表明，每种抑制剂均以剂量依赖性方式与 EGFR-TK 特异性结合。[18

  DOI：

  10.1002/jlcr.3538

文献信息

• Metal-, Photocatalyst-, and Light-Free Minisci C–H Alkylation of <i>N</i>-Heteroarenes with Oxalates
  作者：Jianyang Dong、Zhen Wang、Xiaochen Wang、Hongjian Song、Yuxiu Liu、Qingmin Wang

  DOI：10.1021/acs.joc.9b00972

  日期：2019.6.7

  for metal-, photocatalyst-, and light-free Minisci C–H alkylation reactions of N-heteroarenes with alkyl oxalates derived from primary, secondary, and tertiary alcohols. The protocol uses environmentally benign persulfate as a stoichiometric oxidant and does not require high temperatures or large excesses of either of the substrates, making the procedure suitable for late-stage C–H alkylation of complex

  在此，我们报告了N-杂芳烃与衍生自伯醇、仲醇和叔醇的草酸烷基酯的无金属、光催化剂和无光 Minisci C-H 烷基化反应的温和方案。该协议使用对环境无害的过硫酸盐作为化学计量氧化剂，不需要高温或任何一种底物的大量过量，使得该程序适用于复杂分子的后期 C-H 烷基化。值得注意的是，可以使用该协议对几种药物和天然产品进行功能化或制备，从而证明其实用性。
• Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing
  作者：Zhonghua Li、Tingting Qin、Zhongrui Li、Xuan Zhao、Xinhui Zhang、Taoqian Zhao、Nian Yang、Jinxin Miao、Jinlian Ma、Zhenqiang Zhang

  DOI：10.1016/j.ejmech.2021.113778

  日期：2021.12

  remarkable capacity to inhibit colony formation, suppress migration and induce apoptosis of MGC803 cells. Furthermore, in MGC-803 xenograft mouse model, 5k treatment resulted in significant reduction in tumor size by 81.6% and 96.1% at dosages of 40 and 80 mg/kg/d, respectively. Our findings indicate that erlotinib-based analogs provide a novel structural set of LSD1 inhibitors with potential for further

  组蛋白赖氨酸特异性去甲基化酶 1 (LSD1) 是一种重要的表观遗传调节剂，并以不同的方式参与恶性转化和肿瘤发病机制。因此，LSD1的抑制为癌症治疗提供了一个有吸引力的治疗靶点。基于药物再利用策略，我们筛选了我们内部针对 LSD1 的化学库，发现 EGFR 抑制剂厄洛替尼（一种 FDA 批准的肺癌药物）对 LSD1 的效力较低（IC 50  = 35.80 μM）。在此，我们报告了我们进一步的药物化学努力，以获得高度水溶性的厄洛替尼类似物5k (>100 mg/mL)，其对 LSD1 的抑制活性显着增强 (IC 50  = 0.69 μM) 以及更高的特异性。在 MGC-803 细胞中，5k抑制 LSD1 的去甲基化，表明其对酶的细胞活性。此外，5k具有显着的抑制集落形成、抑制迁移和诱导MGC803细胞凋亡的能力。此外，在 MGC-803 异种移植小鼠模型中，5k治疗导致肿瘤大小分别在 40
• Compounds
  申请人：Hummersone Geoffrey Marc

  公开号：US20060199804A1

  公开（公告）日：2006-09-07

  Compounds of formula I: A-B-C  (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of: where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is: R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is: where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from: which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of:

  化合物的化学式I： A-B-C  (I) 及其异构体、盐、溶剂合物、化学保护形式和前药，其中： B选自以下组合： 其中R N 为H或Me； 或B是含有一个或两个环异原子的二价C 5 杂环残基； A为： R A3 和R A5 独立选择自卤、OR O 和R AC ，其中R O 为H或Me，R AC 为H或C 1-4 烷基； X A 选自N和CR A4 ，其中R A4 选自H、OR O 、CH 2 OH、CO 2 H、NHSO 2 Me和NHCOMe； R A2 和R A6 独立选择自H、卤素和OR O ； 或R A3 和R A4 与它们连接的碳原子一起，或RA2和R A3 与它们连接的碳原子一起，可形成含有至少一个氮环原子的C 5-6 杂环或杂芳环； 如果X不是N，则R A2 至R A6 中的1、2或3个不是H； C为： 其中X选自N和CH，Y选自N和CH，Z选自N和CR C6 ； R C3 选自H、卤素和可选择性取代的含氮C 5-7 杂环基； R C5 为以下组合之一： 该组合可由一个或两个C 1-4 烷基或一个羧基选择； R C6 为H； 或者，当X和Y为N时，R C5 和R C6 （当Z为CR C6 时）与它们连接的碳原子可形成所选自的融合C 6 芳香环之一：
• [EN] AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE<br/>[FR] DÉRIVÉS D'AMINOQUINAZOLINE ET LEURS SELS ET PROCÉDÉS D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2013071697A1

  公开（公告）日：2013-05-23

  The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明涉及医学领域。本文提供了氨基喹唑啉衍生物、其盐和药物配方，用于调节蛋白酪氨酸激酶活性，以及调节细胞间和/或细胞内信号传导。本文还提供了包含氨基喹唑啉化合物的药用可接受组合物，以及使用这些组合物治疗哺乳动物，特别是人类的增生性疾病的方法。
• AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20140228361A1

  公开（公告）日：2014-08-14

  The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明涉及医学领域。本文提供了氨基喹唑啉衍生物，其盐和药物配方在调节蛋白酪氨酸激酶活性以及调节细胞间和/或细胞内信号传导方面具有用处。本文还提供了包含氨基喹唑啉化合物的药用可接受组合物，以及在治疗哺乳动物，特别是人类的增生性疾病中使用这些组合物的方法。